Navigation Links
Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
Date:11/9/2007

dy.

Key Findings to Date from the Phase 2 Study

In June 2006, HGS reported the 52-week results of the Phase 2 trial of LymphoStat-B in patients with SLE. The 52-week results demonstrated that LymphoStat-B significantly reduced disease activity versus placebo in patients with serologically active SLE across multiple clinical measures, exhibited clinically relevant biological activity, and appeared generally safe and well tolerated. Frequency and severity of adverse events were similar to placebo, with no increase at higher doses. Among the findings at Week 52 was a significantly improved response rate among serologically active patients, as defined by an improvement in SELENA SLEDAI score of 4 points or greater, no new BILAG A flare and no more than one new BILAG B flare, and no worsening in Physician's Global Assessment (46% for LymphoStat-B versus 29% for placebo, p<0.01). This combination of measures is the primary efficacy endpoint in the ongoing pivotal Phase 3 clinical trials.

The data presented today at ACR 2007 demonstrated that LymphoStat-B achieved sustained improvement or stabilization of SLE disease activity in serogically active patients through 2.5 years. LymphoStat-B also decreased the frequency of SLE disease flares in these patients over time. The overall incidence of adverse events and laboratory abnormalities remained stable or decreased from Week 52 to Week 128.

The evidence of sustained clinical effect in serologically active SLE patients from Week 52 to Week 128 includes:

-- An increase from 46% to 54% in the combined patient response rate

selected as the primary efficacy endpoint of the Phase 3 trials. Among

serologically active subjects who completed 128 weeks of treatment

(n=175), 63% responded based on this measure of clinical effect.

-- An increase from 49% to 58% in the proportion of patients who had

improvement in SLE disease activity, as measured by SELENA SLEDAI'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , Sept. 1, 2015   Alpha Imaging LLC , ... Cleveland announced today that they have been awarded ... X-ray imaging systems in Michigan.   The new territory supplements Alpha Imaging,s ... states including Ohio , Indiana ... Maryland , West Virginia , ...
(Date:9/1/2015)... Taiwan,s GNT Biotech ... Taipei on  August 25 th ... a targeted drug delivery technology that uses nano-scale gold ... part of a joint press conference held by its ... showcasing GNT,s latest edible gold-based food and beverage partners, ...
(Date:9/1/2015)...   Ivenix Inc. , a medical technology ... on a $42M round of equity financing led ... CICA, Inc., Easterly Capital, Fidelity Biosciences, and SCP ... financing will support the company,s efforts to enter ... acted as the exclusive placement agent for the ...
Breaking Medicine Technology:Alpha Imaging Expands Shimadzu Territory 2GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 2GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 3GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 4GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 5Ivenix Inc. Secures $42 Million in Funding 2Ivenix Inc. Secures $42 Million in Funding 3
... N.J., Nov. 5 Medarex, Inc.,(Nasdaq: MEDX ... milestone payment of,an undisclosed amount from its licensing ... Phase 2 trial of CNTO 95, a fully ... in tumor-induced,angiogenesis. The CNTO 95 human antibody was ...
... Largest Study of Its Kind, PASADENA, Calif., Nov. 4 ... of 37.2 percent -- and as much as 50,percent -- ... Kaiser,Permanente Southern California. The study was published online on November,3 ... journal., The largest study of its kind, the five-year ...
Cached Medicine Technology:Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors 2Healthy Bones Program Reduces Hip Fractures by 37 Percent, Kaiser Permanente Study Finds 2Healthy Bones Program Reduces Hip Fractures by 37 Percent, Kaiser Permanente Study Finds 3Healthy Bones Program Reduces Hip Fractures by 37 Percent, Kaiser Permanente Study Finds 4
(Date:9/1/2015)... ... 2015 , ... Celebrity hairstylist and Beauty Gives Back Art Team member Ted ... on Thursday, Oct. 1, at the La Valencia Hotel. The presentation, on the eve ... fashion and professional hair, makeup and nail design. , The evening of beauty ...
(Date:9/1/2015)... ... ... Philanthropic giving in the U.S. has been stuck at 2% GDP since ... released today by Camber Collective, goes to the root of this problem and provides ... in new philanthropic giving and shift $25B that’s already being donated, according to the ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... colleges and universities across the country in stemming sexual assaults on their campuses. ... Collaborative (ARC3), a consortium of sexual assault researchers and student affairs professionals responding ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... members of the American Society for Dermatologic Surgery, according to a new survey ... ASDS Consumer Survey on Cosmetic Dermatologic Procedures – which reflects views on cosmetic ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... Splashtop Business for Remote Support , a solution optimized for MSPs and ... with the escalating renewal prices and inadequate customer services of existing remote support ...
Breaking Medicine News(10 mins):Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 3Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 2Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 3Health News:Georgia State, Partners Introduce Climate Survey to Aid in Preventing Campus Sexual Assaults 2Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 2Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 4
... disease, treatment response , THURSDAY, Feb. 18 (HealthDay News) -- ... a cancer, and then use that fingerprint to track the ... "[This technique] will allow us to measure the amount of ... is identified by biopsy," said study co-author Dr. Luis Diaz, ...
... , , PITTSBURGH , Feb. 18 ... use of a drug that illuminates brain tumor cells to ... to surgically excise tumors and improve patient survival. , AGH ... approved by the U.S. Food and Drug Administration to investigate ...
... University of Florida aquatic animal health experts say dolphins ... cervical cancer in people. "We discovered that dolphins ... be linked with cervical cancer in women," said Hendrik ... at UF,s College of Veterinary Medicine today (Feb. 18) ...
... ... Health of Illinois has been designated as a Health Information Technology “Regional Extension Center” ... primary care practices, federally qualified health centers, and critical access hospitals with the selection ... ...
... ... to land an NFL Draft pick would have to find a personal ... specialists to help them compete with the best athletes in the world. ... Athletes, Performance has offered an NFL Combine preparation program, and this year ...
... It is not unusual to hear people blame their metabolism after ... that shapes how our bodies turn food into energy -- can ... into your favorite jeans. In fact, differences in metabolic ... though the mechanism behind it is unclear. Now new research from ...
Cached Medicine News:Health News:Scientists Spot Genetic 'Fingerprints' of Individual Cancers 2Health News:Scientists Spot Genetic 'Fingerprints' of Individual Cancers 3Health News:Pittsburgh Neurosurgeons Explore Use of Drug that Illuminates Brain Tumor Cells To Guide Surgery 2Health News:Pittsburgh Neurosurgeons Explore Use of Drug that Illuminates Brain Tumor Cells To Guide Surgery 3Health News:Dolphins could be ideal model to study human cervical cancer, UF veterinarians say 2Health News:Electronic Health Record Assistance for Central Illinois Medical Practices 2Health News:Electronic Health Record Assistance for Central Illinois Medical Practices 3Health News:Electronic Health Record Assistance for Central Illinois Medical Practices 4Health News:Small Time Company Rolls into the Big League: Trigger Point Performance Therapy Selected to Attend Athletes' Performance NFL Combine Preparation Program 2Health News:Small Time Company Rolls into the Big League: Trigger Point Performance Therapy Selected to Attend Athletes' Performance NFL Combine Preparation Program 3Health News:Chemical tags likely to affect metabolism, cancer development 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: